abortion
and fetal tissue transplantation, 6, 8, 10-12, 22, 24, 39, 43, 72, 135-136, 151-159
informed consent issues, 13
types of, and morally relevant differences among them, 153
acetylcholine, 35, 74-75, 97, 98
acetyl-L-carnitine, 99
adrenal cells, see adrenal cell grafts; chromaffin cells
adrenal cell grafts
age of donor and, 66, 71, 93-94
animal experiments with, 65-66
with antiparkinson drugs, 70-71
cell survival rates, 65-66
clinical studies of, 68-71
developmental state of material and success of, 49
disruption of blood-brain barrier, 53
effectiveness of, 65, 66, 69-71
for Huntington’s disease, 73
mortality rates, 68, 69-70
with nerve growth factor, 66, 71
for Parkinson’s disease, 6, 7, 21-22, 23, 45, 52, 62, 65-66, 68-71
for progressive supranuclear palsy, 71
psychological effects of, 52
registries, 69-70
adrenocorticotropic hormone, 106
Agency for Health Care Policy and Research, 15, 129
AIDS, 53, 140
alcohol-dated memory loss, 74
Alcohol, Drug Abuse, and Mental Health Administration
funding of neural grafting research, 4, 24
peer review process, 12
allografts, 23, 50, 52, 78
FDA regulation of, 126
aluminum and aluminum binding, 98
Alzheimer’s disease, 7, 19
animal model of, 74
diagnosis, 98
incidence and prevalence of, 3, 93, 99
naturally of fictional loss in, 20, 74, 98
pharmacological treatment of, 98-99
potential of neural grafts for, 7, 74, 75-99
consequences, 98
Alzheimer’s disease-associated protein, 98
amantadine, 97
American Association of Neurological Surgeons, 70
amygdala, 98
amyotrophic lateral sclerosis, 7, 20
diagnosis, 99-100
incidence and prevalence of, 3, 93, 100
mortality rates, 100
nature of functional loss in, 99
potential of neural grafts for, 75, 100
symptoms of, 99
amyotrophic lateral sclerosis-Parkinson’s disease-dementia, 96
animal models
of Alzheimer’s disease, 74
analogous, 61
of epilepsy, 82
excitotoxin, 73
homologous, 61
MPTP, 63-64, 69
need for, 61, 84
of neuroendocrine deficits, 83
6-OHDA, 63, 65, 66
of parkinsonism, 23, 43, 45, 63
of spinal cord injury, 78
of stroke, 81, 104
animal research on neural grafting
with adrenal medullary tissue, 65-66
for Alzheimer’s disease, 74-75
for amyotrophic lateral sclerosis, 75
for brain injuries, 81-82
for epilepsy, 82
extrapolation to humans, 63
with fetal CNS tissue, 42-43, 65, 72
focus of, 61
with genetically engineered cells, 66-67
for Huntington’s disease, 73
with mature CNS tissue, 49
for multiple sclerosis, 84
for Parkinson’s disease, 6, 63-67
with peripheral nerve tissue, 43-44
for spinal cord injuries, 78-79, 80
transition to human studies, 11, 14, 22-23, 39, 127-128
typeS of, 61
antioxidant, 101
aspirin, 104
astrocytes, 29, 30
effects of grafts from, 47
function of, 35
gene recombinant of, 48
autografts, 23, 43, 45, 50, 65, 69, 78
FDA regulation of, 126, 127
of genetically engineered cells, 127
autonomic nervous system, structure of, 32
axons
communication along, 32
function of, 30, 31, 76
growth/regrowth of, 34-36, 43, 66, 78
structure of, 29
synaptic pattern of, 34
basal forebrain, 98
basal ganglia, 31, 102
basic research on neural grafting, 3
Federal funding of, 3, 4
focus of, 61
needs, 3, 4, 19, 21, 39, 53
benztropine, 97
beta-amyloid, 98
Beta-N-methyl amino-L-alanine, 96
biological rhythms, 42-43
Biomedical Ethics Advisory Committee, 131
Biomedical Ethics Board, 131
blood-brain barrier, 40
development within grafts, 50, 51
disruption by implantation of tissue in CNS, 50, 52, 53
species differences in, 64
brain
developmental sequence in humans, 33-34
immunological privilege, 23, 51
injury response mechanisms, 66
replacement of lost structures in, 41-42
structure of, 30-31
ventricles, graft placement in, 51, 52
brain-derived neurotrophic factor, 36
brain injury, 7, 19
animal experiments on, 81
causes of, 101-102
function of neural grafts in, 7, 20, 82
functional recovery from, 81, 82, 103-104
incidence and prevalence of, 3, 93, 102-103
mortality rates, 103
nature of, 20
neurotrophic activity at wound site, 36
from surgical procedure for graft placement, 52
see also stroke
brain stem, 31, 32, 80
bromocriptine, 97
calcium channel antagonists, 101
captopril, 99
carbidopa, 96
carotid body cells, 45, 65
catecholamines, 79, 80
cell lines, 39
fetal tissue to start, 10
see also continuous cell lines
cell suspensions, 46-47, 49, 62, 72, 79, 82
blood vessel formation in, 51
cells in culture
advantages of, 47-48
allografts, FDA regulation of, 127-127
see also continuous cell lines
central nervous system
fetal, 5
immunological privilege, 50, 51
lymphatic drainage, 50
organization/structure of, 4, 5, 29, 30-32
regrowth/regeneration in, 4, 34-35
see also brain; CNS tissue grafts; spinal cord; and other specific components
cerebral cortex, 30, 31, 74, 81, 97, 98
cerebrospinal fluid, 51
cerebrovascular disease, 102
CHAMPUS insurance program, 14
chromaffin cells, 23, 45; see also adrenal cell grafts
ciliary neurotrophic factor, 36
clinical research on neural grafting
with adrenal cells, 67, 68-71
cognitive limitations of patients and, 10
coordination of, 15, 72-73
ethical issues, 3, 10, 161-163
Federal regulation of, 8, 13, 14, 113
with fetal CNS cells, 67, 71-72; see also fetal CNS tissue grafts
grievance mechanisms for patients, 121
informed consent for, 8, 10, 113, 114-116, 119-121
for Parkinson’s disease, 14, 21, 43, 61, 67-73, 161-162
on particularly vulnerable groups, protection of, 116, 119, 121-122
privately funded, 11, 12
protection of neural graft recipients, 8, 10, 12, 13, 23, 113-119-129
protocol review and approval, 8, 14
selection of subjects, 8, 113
State regulation of, 12, 113-116
surgical procedures, 67-68
withdrawal from experiments, 120
see also human studies
CNS tissue grafts
adult, 23, 49
for demyelinating disorders, 84
see also fetal CNS tissue grafts
continuous cell lines
excessive growth of, 52
grafting with, 47-48
ownership of, 159-161
Coordinated Framework for the Regulation of Biotechnology, 122
corticosteroids, 101
cryopreservation
of adrenal medullary tissue, 68
of fetal CNS tissue, 43, 45, 46
cycads, and ALS-P-D syndrome, 96
dementia, prevalence in United States, 99, 102
demyelinating disorders, 7, 20, 102
nature of functional loss, 21, 83
see also multiple sclerosis
dendrites
communication along, 32
growth of, 34
structure of, 29
Department of Defense, 8, 14
Department of Health and Human Services
Ethics Advisory Board, 12
moratorium on Federal funding of human fetal transplantation research, 6, 11, 24, 39, 67, 72, 128, 149, 151, 154, 171-173
protection of neural graft recipients, 8, 12, 13, 23, 113
see also Food and Drug Administration; Public Health Service
Department of Veterans Affairs, 14-15, 129
funding of neural grafting research, 4, 8, 24
spinal cord injury centers, 102
deprenyl, 64, 96, 150
DiGeorge’s syndrome, 151
dopamine-producing cells, 23, 45, 62, 67
dorsal roots, regeneration of, 78
Dunn, E., 21
encephalitis, 53
endothelial cells, 51
epidermal growth factor, 36
epilepsy, 7, 20, 21
  animal model of, 82
  characteristics of, 21, 104
  chug management of, 105
  function of neural grants in, 7, 105
  incidence and prevalence of, 3, 93, 102, 105
  types of seizures, 104-105
ethical issues
  continuous cell line ownership, 159-161
  Federal funding and, 9-10, 149-151
  fetal tissue, 151-159
  human subjects in research, 3, 10, 161-163
  Nuremberg Code, 114
  research abuses, 114
  sources of materials for transplantation, 3, 6, 10, 22, 23-24, 151-161
see also medical research ethics
excitotoxins, 73
experimental allergic encephalomyelitis, 53
Federal Food, Drug, and Cosmetic Act, 122, 123, 125
Federal funding
  ethical issues in, 149-151
  moratorium on human fetal tissue transplantation research, 6, 11, 24, 39, 67, 72, 128, 149, 151, 154, 171-173
  of neural grafting research, 3, 24, 151
  regulations affecting, 8
fetal research
  abortion and, 135-136
  on cadavers (fetal), 135, 152
  disposition of remains, 138-139
  ethical issues in, 152
  Federal policy development on, 130-131
  Federal regulations on, 131-132, 138-139
  grafting, see fetal CNS tissue grafts
  guidelines on, 8-9
  interstate transfer of a fetus, 137
  on live fetuses, 131-132, 135, 153
  State regulations on, 9, 132-135
fetal CNS tissue grafts, 39
  acetylcholine-producing, 75
  advantages over other tissues, 43, 49
  for Alzheimer’s disease, 74, 75
  animal experiments with, 4243, 63, 65
  behavioral control with, 4243, 83
  blood vessel formation in, 51
  for brain injuries, 82
  brain stem cells, 80
  from cell suspensions, 46
  clinical trials, 71-72
  constraints on use of, 4, 6, 43, 65, 67, 73
  continuous cell lines from, 136
  cryopreservation of cells, 43, 45, 46
  effectiveness of, 4, 22, 42, 53, 65, 66, 72
  for epilepsy, 82
  ethical issues in use of, 151-159
  FDA regulation of, 23, 126, 127
  Federal oversight of, 9, 138-139
  for Huntington’s disease, 73
  identification of fetal brain region for materials, 43
  from induced abortions, 6, 10, 12, 13, 39, 152-157
  informed consent conditions, 12, 13, 120, 132, 155-156
  integration into mature CNS, 42
  manner and timing of procurement of tissues, 12, 23-24
  norepinephrine-containing, 75
  number of cells used, 43
  for Parkinson’s disease, 6, 22, 43, 52, 62, 63, 65, 67, 71-72
  and property rights, 10
  protection of donors of, 8-9, 129-137
  and respect for fetal life, 10, 152-152
  risks to recipients, 43, 136, 152-153
  sale of materials, 9, 12, 13, 24, 130, 131, 136-137, 140-142, 157-159
  for spinal cord injuries, 78-80
  spinal cord tissue, 78-79
  spinal motor neurons, 75
  as standard therapy, 157-158
  survival of grafts, 72
  fibroblast growth factors, 36
  fibroblasts
    genetic engineering of, 48
    risk from use in grafts, 48, 53
    tyrosine hydroxylase production by, 66
  Food and Drug Administration, regulatory authority
    biological products, 123
    devices, 123
    drugs, 122-124
    interstate commerce and, 124-125
    limits on, 124-126
    neural graft materials, 8, 14, 23, 122, 126-127
    practice of medicine and, 125-126
    product safety and efficacy, 123-124
    funding, see Federal funding
  gamma-aminobutyric acid, 82, 97, 105
  ganglia, 32
  General Registry of Adrenal-Fetal Transplantation, 70
  genetically engineered cells, 39, 65
    animal studies with, 66-67
    autografts of, 127
    ethical issues related to, 161
    FDA regulation of, 127
    grafting methods, 6, 48, 67
    NGF-producing, 75
  glia-derived nexin, 36
  glial cells
    differentiation of, 34
    function of, 29, 30, 83
    inhibition of neuron regrowth, 40
    primary cultures of, 47
    replication of, 34
    Structure of, 29-30
    types of, 29, 30
  gonadotrophin-releasing hormone, 83
  Health Care Financing Administration, 8, 13, 129
  heart transplants, funding controversies, 150
  hepatitis, 53
  herpes simplex, 53
  hippocampus, 74-75, 82, 98
  HIV, 140
  human amnion membrane matrix, 45
  human studies, see clinical research on neural grafts
Huntington's disease, 7, 20
cause of, 73, 97
functional loss from, 73, 97
incidence and prevalence of, 3, 93, 97-98
potential of neural grafts in, 7, 73
symptoms of, 73, 97
treatment of, 97
hyperexcitable nerve cells, 105
hypothalamus, 31, 82, 83
idebenone, 99
immune system response
to allografts, 52
to cell suspensions versus solid tissue grafts, 47
developmental state of graft material and, 49
to fetal CNS tissue, 43, 49
to genetically engineered cells, 48
multiple sclerosis and, 106
Parkinson's disease and, 52
prevention of, 50
source of tissue and, 5, 45, 50-51, 53
to surgical procedure, 52
immunological privilege, 23, 50, 51
immunoreactive molecules, 50-51
immunosuppression, risks to graft recipients, 52
infections from grafting materials, 53
informed consent
for donation of continuous cell lines, 159-161
ethical issues, 162-163
for fetal tissue donation, 12, 13, 132, 155-156
information to be provided for, 119-121
from particularly vulnerable populations, 121-122
from patients in clinical studies, 8, 10, 113, 119-121
penalties for violation of, 120-121
State regulations on, 114-116, 119-121
withdrawal from experiments, 120
injury, see brain injury; spinal cord injury
Institutional Review Boards, 8, 12, 14, 15, 23, 161
composition of, 118
criteria for authorization of human research, 117
ethical guidelines, 117-118
Federal requirements for review by, 129
procedure for obtaining approval of, 118
purpose of, 113, 116-119
State requirements for review by, 122
insulin and insulin-like growth factors, 36
Interagency Head Injury Task Force, 102-103
interstate commerce, and regulation of neural grafting, 124-125
isografts, 50
Joint Commission on Accreditation of Healthcare Organizations, 8, 129
L-dopa
production by genetically engineered cells, 48
treatment of Parkinson's disease with, 95-97, 150
laminin, 36
legal/regulatory issues
constitutionality of restrictions on research, 9, 137-138
disposition of cadavers/fetal remains, 9, 13, 138-139
Federal oversight, 9, 14, 137-142
fetal research, 131-132, 138-139
grievance mechanisms for patients, 121
indirect regulation, 8, 14, 129
informed consent, 8, 12, 13, 119-121
neural graft materials, see Food and Drug Administration
ownership of continuous cell lines, 159-161
payment of donors, 8, 9, 140-142
protection of donors of fetal tissue, 8-9, 129-137
protection of human subjects in research, 8, 13, 22, 113-129;
see also clinical research on neural grafting; informed consent; State laws
see also specific statutes
limbic system, 31
locus ceruleus, 82, 98
Lou Gehrig's disease, see amyotrophic lateral sclerosis
Medical Device Amendments of 1976, 124
medical malpractice, 8
medical research ethics, genesis of, 114
Medical Treatment Effectiveness Program, 15
Medicare/Medicaid coverage, 14, 129
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 64, 95
methylprednisolone, 101, 106
methylpyridine, 64
microglia, 29, 30
milacemide, 99
monoamine oxidase B, 64
moratorium on Federal funding of human fetal transplantation research, 6, 11, 24, 39, 67, 72, 128, 149, 151, 154, 171-173
motor neurons, neural grafting with, 100
motor neuron disease
potential of neural grafts in, 7, 75
see also amyotrophic lateral sclerosis
MPTP model of parkinsonism, 63-64, 95
multiple sclerosis, 7, 21
causes of, 105-106
death rates, 106
diagnosis of, 106
drug therapy, 106
and immune system function, 106
incidence and prevalence, 3, 93, 106-107
potential of neural grafts in, 84, 106
symptoms of, 105
myelin
formation of, 34, 43, 47, 83
function of, 29, 43
loss of, 21, 105; see also multiple sclerosis
naloxone, 101
National Academy of Sciences, 12
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 130, 151-152
National Conference of Commissioners on Uniform State Laws, 13, 140
National Institute of Neurological Disorders and Stroke, 70
National Institutes of Health
budget, 113
funding of neural grafting research, 4, 24
guidelines for neural grafting research protocols, 15
guidelines for research on vulnerable subjects, 121
Human Fetal Tissue Transplantation Research Panel, 12, 154
peer review process, 12
National Organ Transplant Act
components covered under, 13-14
fetal tissue regulation under, 9, 12-13, 141, 157
National Research Act, 130
National Science Foundation, funding of neural grafting research, 4, 24
nerve fibers, 45,62
nerve growth factor
with adrenal cell grafts, 66,71
and Alzheimer’s disease, 98
production by genetically engineered cells, 48
protection of acetylcholine neurons, 75,98-99
role of, 36
stimulation by grafts, 41
nerve roots, 31-32
nervous system
 cellular components of, 29-30; see also glial cells; neurons
 chemical-electrical communication in, 32-34
 fetal (human), 43
 organization/structure of, 4,5, 29-32
 see also brain; central nervous system; peripheral nervous system; spinal cord; and other specific components
 neural grafting
 age of host and, 51-52,53,78-79
 alternatives to, 150-151
 and blood vessel formation, 51, 53
 definition of, 3,4,39
 effectiveness on neurological disorders, 19,61,63-64,93
 Federal interests in, 22-24
 historical perspective, 21-23,42
 with immature versus mature tissue, 5, 21,49,52,53,66
 number of cells used in, 52
 number of recipients, 19
 Nuremberg Code applied to, 114
 psychological effects of, 52,69
 replacement of chemicals with, 19,20, 3940,42
 replacement of lost structures with, 19,20,39,41-42
 risks to recipients, 5, 42, 52-53, 81, 152-153, 161-162; see also immune system response
 site for transplantation, 44, 62, 63,72
 stimulation of cell growth and survival with, 19,20,40-41,63, 80
 success factors in, 5,49-51
 therapeutic strategies, 4, 19,39-42
 neural grafting materials, 4-5,6,53
 ethical and legal questions, 42, 151-161; see also ethical issues; legal/regulatory issues
 excessive growth of, 52
 immunological problems of, 42
 infections from, 53
 man-made, coated with growth-promoting chemical, 45
 regulation of, 8, 23, 122
 sources of, 23,39,42
 see also adrenal cell grafts; fetal CNS tissue grafts; genetically modified cells
 neuritic plaques, 98
 neuroblastoma cells, 47
 neurodegenerative disorders, 20
 characteristics of, 20
 potential function of neural grafts in, 7
 see also specific diseases
 neuroendocrine deficits, 7, 82-83
 neurofibrillary tangles, 98
 neurological disorders
 animal models of, 43
 costs of, 7, 93, 150
disease, 20-21; see also neurodegenerative disorders, and specific disorders
 epidemiology of, 94-100
 incidence and prevalence of, 3, 19,93
 injury, 20; see also brain injury; spinal cord injury
 nature of, 20-21
 potential of neural grafting for, 150
 treatment approaches, 3,7, 19,21
 in veterans, 102
 see also specific disorders
 neuromuscular diseases, 102
neurons
death of, 34,41,94,97,98
 differentiation of, 34
 injured, 40-41
 number of, 34
 peripheral autonomic, 5
 primary cultures of, 47
 regeneration of, 29, 34-35,40,45
 structure of, 29
 survival of grafting procedures, 43,47
 see also axons; dendrites
 neurotransmitters, 7,44,45,73
 function of, 32-33
 implants in CNS, 40
 kinds of, 33-34
 see also specific neurotransmitters
 neurotrophic factors, 34, 36,66,79, 82
 neurotrophin-3, 36
 neurotropic factors, 34, 36,79
 nimodipine, 99
 noradrenaline, 82,98
 nucleus/nuclei
defined, 30
 purpose of, 31
 Nuremberg Code, 114
6-OHDA, 63,65,66
 oligodendrocytes
 function of, 29,30,35,47,83
 primary cultures of, 47
 organic brain syndrome, 102
paraneurons, 45
Parkinson, James, 94
Parkinson’s disease and parkinsonism, 7, 19
adrenal cell grafts for, 21-22,45,62,65-66,67, 68-71, 128
animal research on, 23,43,45,63-67
causes of, 95
clinical trials of neural grafting, 14, 21, 43, 61, 67-72, 128, 161-162
drugs used for treatment of, 97, 150
epidemiology of, 94-97
fetal CNS grafts for, 6,22,43,52,62,63,65, 67,71-72,136
genetically engineered cell grafts for, 66-67
incidence and prevalence of, 3,93,95,96-97
mortality rates, 68, 69-70
MPTP model, 63-64,66,95
nature of functional loss in, 20, 62, 94
neural grafting applications, 3, 5, 6, 96
number of recipients of neural grafts, 6, 67
on-off phenomenon, 68
registries, 69-70
site for transplantation, 62, 63
success of neural grafting in, 5, 39, 63, 71, 72, 84, 93, 150-151
surgical procedures for grafts, 67-68
symptoms, 62, 64, 94, 95
treatment of, 95-96
PC12, 47
peripheral autonomic tissue
animal experiments with, 44-45
developmental state of, and success of graft, 49
peripheral nerve cells
function of, 44
grafts with, 23, 39, 43-44, 45, 78, 84
regrowth of, 44
peripheral nervous system
organization/structure of, 4, 29, 32
regrowth/regeneration in, 4, 34-35
tissues used for grafting, 5
physostigmine, 99
pituitary gland, 82
policy issues and options
Federal funding of fetal tissue transplantation research, 11-12
Federal Government role in development of neural grafting procedures, 14-15
laws and regulations applicable to fetal tissue transplantation, 12-14
practice of medicine, and regulation of neural grafting, 125-126
progressive supranuclear palsy, 71
Protection of Human Subjects Act, 155
Public Health Service Act, 8, 122, 123, 125-127
regulatory issues, see legal/regulatory issues
research, see animal research; basic research; clinical research
retrograde cell death, 76, 78
S100 protein, 36
scar formation, 41
astrocytes and, 35, 47
reduction of, 47, 78
Schwann cells, 29, 30
axon regrowth into, 35
function of, 34, 43, 47, 83
from peripheral nerves, 84
in primary cultures, 47
seizures, 21, 53, 82, 104; see also epilepsy
sexual potency/sexual behavior, restoration of, 83
spinal cord
immunological privilege, 51
regenerative capacity, 80
replacement of lost structures in, 41-42, 76
structure of, 31-32, 76
spinal cord injury, 7, 19
age of host and effectiveness of grafts, 78-79
animal models of, 78
causes of, 75, 100
demyelination in, 84
effectiveness of grafts on, 80-81
fetal brain tissue grafts, 79
fetal spinal cord tissue grafts, 78-79
fictional losses from, 102
functional recovery from, 79-80, 80-81, 101
incidence and prevalence of, 3, 93, 101, 102
and neurotrophic and neurotropic factors, 79
peripheral nerve grafts for, 78
potential function of neural grafts in, 7, 76-78, 101
rehabilitative therapy, 81
repair of nerve fibers, 76
research needs on, 80
risks to graft recipients, 81
sources of graft materials, 79
survival rates, 101
State laws
on clinical research, 12, 113-116, 121-122
on compensation for fetal tissue, 140-142
on disposal of fetal remains, 138-139
on fetal research, 9, 132-135
on informed consent, 114-116, 119-121
licensing, 8
on protection of fetus, 132-135
on protection of particularly vulnerable populations, 121-122
on protection of pregnant women, 140; see also informed consent
striatum, 62, 67-68, 72, 73, 97
stroke, 7, 19
animal model of, 81
causes of, 102
functional losses from, 103
incidence and prevalence of, 3, 93, 104
intracranial hemorrhage, 103
ischemia, 103
potential of neural grafting for, 81-82, 104
substantial nigra, 62, 63, 70, 94
surgical procedures
adrenalectomy, 68, 69-70
clinical trials of, 128
complications of, 68, 69-70
effect of graft placement during, 52
effect on success of graft, 66
for epilepsy, 105
open surgery, 67, 69
for Parkinson's disease grafts, 67-68, 72
regulation of, 8, 127-129
stereotactic, 67, 72
suronacrine maleate, 99
sympathetic ganglia, 65
synapses
between graft and host, 40, 62, 63, 73, 82
structure of, 32-33
synaptic contacts, 34, 36, 76, 80
synaptic space, defined, 32
synaptic sprouting, 34-35
tetrahydroaminoacridine, 99
thalamus, 31
Thompson, W. G., 21
thyrotropin-releasing hormone, 101
transplants, tissue and organ, number of recipients, 19
trihexyphenidyl, 97
tumor formation, from continuous cell lines, 48, 52
Tuskegee syphilis study, 114
tyrosine hydroxylase, 66
Uniform Anatomical Gift Act
  amendment of, 13
  applicability to fetal tissue implants, 9,13, 135,136,138-141, 154
ununiform donor card, 139
United Parkinson Foundation, 70

vasopressin, 83
velnacrine maleate, 99
Willowbrook hepatitis study, 114
xenograft, 50, 53